Frost.com - Healthcare Research http://www.frost.com/c/10024/home.do - Healthcare Research Thu, 24 May 2018 8:49:19 Innovations in Nerve Stimulation Therapy, Retinal Prosthesis, Sensory Prosthetic Arm, Brain Neurostimulation Device, and Robotic Surgical Microinstruments http://www.frost.com/prod/servlet/sublib/display-report.do?id=D852-00-1D-00-00 The latest edition of Medical Device TOE profiles a mixed bag of innovations from the wide spectrum of the healthcare industry. This issue profiles several neurostimulation technologies for pain management, physical rehabilitation and for cognitive therapies, along with innovations in diabetes management, tele-surgery, and prosthetic devices. The Medical Device TechVision Opportunity Engine (TOE) analyzes and reports on new and emerging technologies and advances in R&D; product development; and regulatory matters related to neurology, ophthalmology, respiratory/anesthesia, wound care and management, surgical tools and instrumentation, drug delivery, orthopedics, endoscopy, cardiology, and monitoring. Medical devices and imaging technology and innovation research covers cutting-edge global developments in medical devices and imaging sectors such as biosensors, biomaterials, biomechanics, microtechnologies, nanotechnologies, assistive technologies, and imaging technologies and platforms. Keywords: Neurostimulation, pain management, prosthetics, tele-surgery, robotic surgery Fri, 18 May 2018 00:00:00 +0100 Innovations in Predictive 3D Modeling of Live Human Cells, Vaccine Development, Gene Editing, and Targeted Protein Degradation Platforms http://www.frost.com/prod/servlet/sublib/display-report.do?id=D758-00-7A-00-00 This edition of the Genetic Technology TOE depicts life sciences trends across predictive 3D modeling of live human cells, vaccine development, gene editing, and targeted protein degradation platforms. The corresponding clinical trials scenario is also covered. The Genetic Technology TechVision Opportunity Engine (TOE) presents the latest R&D developments and advances with an emphasis on opportunities to profit in the explosive field of genetic technology through technology transfer, joint ventures, and acquisitions. The complete gamut of genetic technology applications is covered including the latest developments in omics technologies; genetic, cellular, and alternative therapies; sequencing technologies; and genetically altered animals and plants. The Health & Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare. Keywords: Predictive 3D modeling, live human cells, vaccine development, gene editing, targeted protein degradation platform, artificial intelligence, food allergy, ubiquitin proteasome mechanism, druggable proteins, RNAi drugs, hereditary amyloidosis Fri, 18 May 2018 00:00:00 +0100 Global Pharma Clinical Trial Patient Recruitment & Monitoring IT Solutions, Forecast to 2020 http://www.frost.com/prod/servlet/sublib/display-report.do?id=K2B4-01-00-00-00 Clinical trial sponsors and clinical research organizations (CROs) are facing intense pressure to change the way clinical research is conducted and justify the costs and time involved in the clinical development process. Some of the prevailing challenges in the clinical trial industry include the complexity and cost of conducting clinical trials, the failure of trials, increasing regulatory requirements for future targeted therapeutics, and the growing number of multi-regional and international trials. Among these, patient recruitment and monitoring activities are considered to be most cost and time-consuming aspect of the clinical trial process. Industry estimates suggest that about 80% of pharmaceutical clinical trials do not meet enrolment deadlines, resulting in an average loss of up to $1.3 million per day for a given drug candidate. Additionally, up to 37% of research sites fail to meet their enrolment targets, and 10% fail to even recruit a single patient for the study. Digitization is playing a critical role in transforming clinical trials model from traditional (centralized) high-cost and difficult-to-access settings to more patient-centric and efficient virtual models. In particular, pharmaceutical companies are seeking to leverage mHealth solutions embracing digital technologies such as wearables, smartphone Apps, and cloud-based remote/virtual clinical trial platform solutions for improving patient engagement, preventing trial failures, and, overall, improving the drug development profitability. Early application of wearable devices and smartphone apps across remote or virtual clinical trial designs demonstrate compelling benefits around optimizing the patient recruitment process by opening up new geographies to increase access to the larger patient population and reduce trial costs by streamlining the trial processes and demonstrating real-world efficacy. Digital e-Recruitment solutions leveraging mHealth technologies and innovative crowdsourcing models promise to drive efficiency and optimize the patient enrichment strategy for future patient-centric clinical trials. This, in turn, would help to improve patient engagement with autonomous and digital workflows (e.g., eConsenting, remote monitoring, virtual training, and reminders) that reduce the burden on the patient and the caregiver. Furthermore, based on research findings, clinical trials industry participants across North America and Europe will continue to the major markets for mHealth technologies application in the clinical trial industry by 2020. Easy access and convenience factors offered by mHealth-enabled remote trials could significantly reduce patients travel cost to the sites as they could now participate from their homes using computers and smartphones, eventually improving retention. mHealth technologies provide new possibilities to capture objective digital biomarker data, increase the reporting quality of clinical trials, and reduce SDV by eliminating errors due to with traditional paper-based reporting by patients or investigators.--BEGIN PROMO--

Research Scope

The research service analyzes the growth opportunities of mHealth technologies across clinical trial remote patient recruitment & monitoring applications. It also evaluates and discusses market projections, key trends, technology lifecycle, and the key implementation challenges of emerging digital solutions. Finally, it provides industry best practices, case studies, cost-benefit analysis, and strategic imperatives for key clinical trial industry stakeholders such as pharma sponsors, CRO, sites, and technology providers.

Key Issues Addressed

  • What are the key trends and growth opportunities tied to emerging digitally-led clinical trials operating models (e.g., remote or virtual clinical trials)?
  • Which emerging tech solutions have the strongest growth potential for optimizing patient recruitment and monitoring workflows (e.g., mHealth, Wearables, etc.)?
  • What are the challenges with current clinical trial patient recruitment and monitoring workflows and how these can be filled by emerging digital health solutions?
  • How does the new ecosystem of digital solution providers look like with specific reference to clinical trials patient recruitment and monitoring?
  • What are the industry best practices for patient recruitment, trial management etc.?
  • What are the key challenges while implementing these digital solutions across the clinical development value chain?
Thu, 17 May 2018 00:00:00 +0100
Innovations in Drug Discovery and Development for Neurological, Cancer, and Cardiovascular Applications http://www.frost.com/prod/servlet/sublib/display-report.do?id=D951-00-1D-00-00 This Drug Discovery TechVision Opportunity Engine (TOE) depicts new life sciences trends across drug discovery platforms focused on neurological, oncological, and cardiovascular application areas. In vivo, in vitro, and in silico models are depicted, integrating the remarkable synergy among biological innovations such as checkpoint inhibitors, stem cells, and transposons, and machine learning artificial intelligence-based approaches. Clinical trials for treatments based on RNA targeting technologies are also depicted. The Drug Discovery TechVision Opportunity Engine (TOE) reports and analyzes about the latest developments in drug discovery and therapeutics, thereby providing an opportunity to acquire strategic insights into crucial developments in this industry domain. Technologies profiled include those used for biomarker and target discovery such as high throughput screening, signal transduction, micro array, RNAi, metabolomics, toxicogenomics, biosensors and nanotechnology. In addition to these, a fair focus shall be dedicated to the latest trends in therapeutic approaches across a diversity of diseases including infectious, genetic, metabolic, neurological, cardiac, and autoimmune disorders. The Health and Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare. Keywords: Animal models, human brain organoids, disease models, biomimicry, neurodegenerative disorders, Zika Virus, CGRP inhibitor, migraine prevention, KRAS, cancer management, tolperisone, neuromuscular spasms, technology convergence, regenerative cardiovascular therapy, regenerative medicine, autophagy, therapeutic breakthroughs, machine learning platforms, drug development, RNA targeting technologies Fri, 11 May 2018 00:00:00 +0100 Recent Advances in Stem Cell Therapies for Gastrointestinal Diseases http://www.frost.com/prod/servlet/sublib/display-report.do?id=D758-00-79-00-00 This edition of the Genetic Technology TOE depicts life sciences trends across stem cell treatments for gastrointestinal disorders. Special attention has been given to stem cell therapy platforms to treat Crohn s Disease, among other gastrointestinal disorders, involving allogeneic and mesenchymal lineage adult stem cells. A summary of clinical trials recruiting patients for stem cell therapy studies is also depicted. The Genetic Technology TechVision Opportunity Engine (TOE) presents the latest R&D developments and advances with an emphasis on opportunities to profit in the explosive field of genetic technology through technology transfer, joint ventures, and acquisitions. The complete gamut of genetic technology applications is covered including the latest developments in omics technologies; genetic, cellular, and alternative therapies; sequencing technologies; and genetically altered animals and plants. The Health & Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare. Keywords: Stem cell therapy, gastrointestinal disorders, allogeneic stem cell therapy platform, mesenchymal lineage adult stem cells, Crohn s Disease Fri, 11 May 2018 00:00:00 +0100 Global Tissue Diagnostics Market, Forecast to 2022 http://www.frost.com/prod/servlet/sublib/display-report.do?id=K25A-01-00-00-00 Tissue diagnostic techniques are used to recognize specific antigens in preserved tissues. The process includes slicing thin tissue samples that are treated with a hematoxylin and eosin (H&E) stain, and then are formalin-fixed paraffin-embedded (FFPE) to diagnose tumors and other histopathology specimens. This has traditionally required skilled pathologists and is one of the most labor-intensive and time-consuming processes of clinical molecular diagnostic testing. It is estimated that 70% of the workflow in a histology laboratory is manual, and therefore, there is a need for automation. The current challenges faced by the industry include shortage of qualified pathologists, consolidation of laboratories leading to shrinkage of the customer base, reimbursement cuts, and competition from novel technologies such as liquid biopsy and next generation sequencing. To address these challenges, vendors have resorted to technology innovation for automation, partnerships with pharmaceutical companies (for companion diagnostics), and information management system (to offer end-to-end solutions) to deepen solution expertise while catering to changing customer demands. Furthermore, the industry is also witnessing collaborations and M&As such as StatLab Medical Products with American MasterTech Scientific.--BEGIN PROMO--

Research Scope

The key objectives of the market engineering for tissue diagnostics study are to highlight current market dynamics, key market participants, customer segments, and evolving business opportunities. The study aims to identify both established enterprises and startups, which are capable of shaping the future through best practices implementation, visionary leadership, and innovation in product offerings. Further, the study provides an analysis of market sizing by revenue segregated by pre-analytical staining, advanced staining, and anatomic pathology laboratory information systems. It covers the key drivers, challenges in the market impeding growth, competitive landscape, market participant strategies, reimbursement scenario, capital pricing, and future growth strategies. The study also highlights growth opportunities, key trends, mergers and acquisitions, notable partnerships, investment, and collaboration opportunities across regions such as the United States, Western Europe, Asia-Pacific, and Rest of the World (ROW).

Major participants mentioned in the study are Roche (Ventana), Leica Biosystems, Agilent (Dako), Sakura, Thermo Fisher Scientific, Biocare Medical, Abbott, Epic Systems, Cerner, NovoPath, and Sunquest, Xifin.

Key Issues Addressed

  • What is the future outlook of tissue diagnostics market in the US, Western Europe, APAC, and Rest of the World?
  • What are the growth opportunities in tissue diagnostics space which can be leveraged by existing and future participants?
  • What constitutes a complete tissue diagnostics vendor landscape? How has the competitive landscape been characterized? Which vendors are dominating the market?
  • How will the structure of the market change over time? Is it ripe for acquisitions?
  • What are the key challenges that affect the uptake of automated systems in the US, Western Europe, APAC, and ROW?
Thu, 10 May 2018 00:00:00 +0100
Innovations in Cell Targeting and Reprogramming http://www.frost.com/prod/servlet/sublib/display-report.do?id=D758-00-78-00-00 This edition of the Genetic Technology TOE depicts trends across cell targeting and reprogramming. Breakthrough technologies, such as gene editing, senescent cells, immune system programming, and tumor microenvironment tuning are depicted by profiling most significant innovations. The corresponding clinical trials scenario for senescent cells targeting is also depicted. The Genetic Technology TechVision Opportunity Engine (TOE) presents the latest R&D developments and advances with an emphasis on opportunities to profit in the explosive field of genetic technology through technology transfer, joint ventures, and acquisitions. The complete gamut of genetic technology applications is covered including the latest developments in omics technologies; genetic, cellular, and alternative therapies; sequencing technologies; and genetically altered animals and plants. The Health & Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare. Keywords: Autologous cell therapy, immune system programming, precise targeting, senescent cells, age-related diseases, gene editing, genome editing, tumor microenvironment, cancer, oncology, immuno-oncology, immune response, MPS Type I, Hurler s syndrome, hemophilia a factor viii deficiency, recessive dystrophic epidermyolysis bullosa, DNA targeting intervention, precision gene replacement, rare diseases, ubiquitin signaling cascade Fri, 4 May 2018 00:00:00 +0100 Breakthrough Innovations in PoC Diagnostics for Smart Healthcare http://www.frost.com/prod/servlet/sublib/display-report.do?id=D817-01-00-00-00 Today, the healthcare industry is focused toward patient centric care and preventative healthcare. Preventative healthcare involves regular screening and diagnosis for diseases before the condition becomes fatal. Early diagnosis improves the clinical outcome of the patients, reduces emergency visits, and subsequently healthcare costs. Usually, early diagnosis is enabled by point-of-care testing (POCT) devices, where physicians or even the patients can check themselves for various conditions and monitor their chronic diseases, at the point-of-care, bringing healthcare services closer to the patients. This research service showcases the trends and applications of POCT devices. The growing importance and benefits of the POC devices are discussed in this research service. This research service focuses on the technology innovations of blood glucose POCT, POC infectious disease diagnosis, POC cancer screening, and POC neurological screening. This research service focuses on technology innovations, key innovators in this space, industry trends, drivers and challenges, and its market impact. Wed, 2 May 2018 00:00:00 +0100 Global Digital Health Maternal and Infant Care Solutions Market Leaders, Innovators, and Startups, 2018 http://www.frost.com/prod/servlet/sublib/display-report.do?id=MDEA-01-00-00-00 BabyTech (digital tools targeted at infants/toddlers) and FemTech (digital solutions for helping women with their health issues) are the latest trends in the healthcare industry. Digital health tools are finding applications in all areas of parenting fertility, pregnancy, birthing, nursing, baby health, and safety. Women form nearly half the population and are the key decision makers at home. Public health concerns such as rising pre-term births and maternal mortality rates are strong factors that are encouraging consumers, healthcare providers and other stakeholders to use digital health solutions to better manage the entire birth continuum, from conception, to birth, and during the first years of infant care. Many factors are driving increased focus from key healthcare stakeholders paving the way for more innovative and targeted digital health solutions. Regulatory bodies and the investment community both realize the potential and applications of digital health tools in this space and have been willing to give it the focus it truly deserves. However, lack of awareness of these tools and their advantages among women and healthcare providers, lack of clear reimbursement policies, accuracy and data security/privacy are factors that need to be addressed by companies in this area. The maternal and infant care space continues to evolve along with major technology and health trends; this is creating a dynamic and exciting area for both vendors and users of these offerings. Moving forward, companies will look at increasingly integrating AI capabilities to yield optimal utility from data in a progressive way as well as leveraging Virtual Assistants as part of user-platform experiences, paving way for non-healthcare companies such as Amazon, Google and others to become key participants in this market. More companies will create products to form a connected home ecosystem the Smart Nursery; these products are interoperable devices that can be managed from the user s smartphone. Frost & Sullivan also expects to see more companies investing in clinical studies,which aim to validate the accuracy of digital health applications in this area as part of further validation, and needed data to support potential claims or other business model aspirations. This report identifies the movers and shakers (companies-2-action) in the maternal and infant care market for digital health, namely, innovative and visionary companies that are creating the market and shaping its trends and growth opportunities moving forward.--BEGIN PROMO--

Key Issues Addressed

  • What are the current digital health opportunities in the maternal and infant care space?
  • Which unique companies are introducing new and innovative solutions?
  • How are connected home progressions impacting the healthcare market in this area?
  • How will AI play a role in maternal and infant care technology?
  • What are the key success factors in this market?
Wed, 2 May 2018 00:00:00 +0100
2018 Top Technologies in Medical Devices & Imaging http://www.frost.com/prod/servlet/sublib/display-report.do?id=D821-01-00-00-00 TechVision's Medical Devices and Imaging technology cluster's flagship research service profiles ten cutting-edge medical technologies that are expected to have a huge impact on the healthcare industry in the next two years. Each of technologies that have been profiled here represent billions of dollars in market potential, and have a rich track record of R&D funding, intellectual property (IP) activity and a vibrant innovation ecosystem. Each of the technology profiles covers the following: Brief technology snapshot, breadth of applications, key innovations and innovators, five-year market potential, recent funding and business deals, important market factors aiding and hindering growth. This list includes technologies that are just seeing the light of commercialization, as well as those technologies that are already in the market, but are expected to make an impact through wide-spread adoption. This research service is a product of a year-long scout of the MedTech industry and other adjacent innovation clusters. This report aims to provide a snapshot of the top medical technologies, serving as a strategic guide to innovators and senior management, helping companies in innovation planning and decision-making. Mon, 30 Apr 2018 00:00:00 +0100 2018 Top Technologies in Sensors & Instrumentation http://www.frost.com/prod/servlet/sublib/display-report.do?id=D82D-01-00-00-00 The technology and innovation research report covers the top 10 Sensors and Instrumentation technologies that will have highest impact in the near-to medium-term. Key technologies in the Sensors and Instrumentation cluster were evaluated to arrive at the top 10 technologies for 2018. The technologies were selected after critical evaluation of an exhaustive list of technologies using TechVision's proprietary selection methodology. The research service assesses technologies from various aspects such as nature of disruption, key technology drivers, market potential, patents, funding, applications and megatrends impacted. The top 10 technologies covered in this research service are Biosensors, LiDAR sensors, Sensor Fusion, ADAS, Smart sensors, Photonic Sensors, Gesture Recognition, Large area sensors, Energy Harvesting and Electronic Skin/ Skinput. Research focus areas will continue to include capabilities beyond sensing that is being more intelligent or smart and including plug-and-play features. Some of the features include enhancing automation levels, miniaturization, intelligence, and reducing cost (while still trying to be profitable and maintaining competitive advantage). IoT concept will be key aspect in driving innovations in sensors segment. Wearables and sensors will drive opportunities in advanced healthcare and medical diagnostics and home monitoring applications. Smart wearables will involve deeper patient engagement leading to predictive healthcare. Sensor fusion systems, where information from different sensors such as LiDAR and smart sensors are combined to achieve higher accuracy are expected to transform advanced driver assistance systems (ADAS) and move automation (highly automated driving (HAD)) to the next level. Mon, 30 Apr 2018 00:00:00 +0100 2018 Top Technologies in Health & Wellness http://www.frost.com/prod/servlet/sublib/display-report.do?id=D80A-01-00-00-00 TechVision s annual Top 10 Health and Wellness Technologies research delivers cutting-edge insights about the 10 most valuable and disruptive technologies poised to impact global healthcare industry in the next 18 months. The chosen 10 technologies have the highest innovation index and were selected using a proprietary methodology based on several criteria, such as industry adoption, IP activity, funding, and market potential among others. These hottest technologies pack maximum potential to fuel global innovation, spawn innovative products, and drive commercial growth. This comprehensive research offers strategic guidance and actionable ideas to executives in innovation-focused organizations. Mon, 30 Apr 2018 00:00:00 +0100 Global Hospital-based Medical Device Connectivity Market, Forecast to 2022 http://www.frost.com/prod/servlet/sublib/display-report.do?id=MBB7-01-00-00-00 For the last few years, healthcare providers globally have been focusing on implementing Electronic Medical Record (EMR) systems and fine-tuning workflow and functionalities to best suit end-user needs. In many countries, the implementation of EMRs has seen high adoption and has been quite successful. It is widely accepted that there can be many potential improvements in the care delivery process and patient safety through the effective use of an EMR. It is not the time for the industry to be complacent. Hospitals are tasked with the need to do more with less, while also keeping pace with technology and patient expectations. In many hospitals, nurses and clinical staff spend half of their working hours per shift on documentation activities, whereas they should ideally be spending most of their focus on direct patient care. What is the advantage of having expensive EMRs when providers have to note patient vitals and key parameters in some cases still on paper and manually key-in those into the electronic record? Improved care coordination also requires accurate, complete, and automated data capture. Medical device connectivity and interoperability is quickly becoming a top priority at hospitals and in healthcare settings because of the numerous benefits it offers across the care continuum. A well-established device connectivity strategy can help hospitals implement clinical alarms based on early warning scores, automated electronic charting, emergency alert and response systems, virtual intensive care units (ICUs), continuous patient surveillance and remote patient monitoring, medical device asset management, and real-time location solutions. The high-acuity care environment is dynamically changing globally, especially with regard to operating rooms, intensive care units and their workforce. The growing shortfall of intensive care workforce is challenging the ability of hospitals to care for critically ill patients. There is a growing need for intensivists and trained nursing staff to care for critically ill patients in acute care settings. In many countries, a shortfall of intensivists poses a real challenge; there is either a short supply or they are entirely absent, with workloads being shared by non-trained hospital personnel. It is quite evident that expert care from specialists can improve patient outcomes and shorten hospital stays, thereby reducing costs and minimising length of stay and readmissions. As an alternative to critical care delivery models, hospitals can leverage EMRs and medical device connectivity solutions to overcome the shortages of intensivists in the high-acuity care environment. Medical devices compliant with the healthcare enterprise (IHE) patient care device (PCD) regulation can establish connectivity with the enterprise hospital network for sharing patient-generated data. A centralised patient surveillance platform offering end-to-end medical device connectivity acquiring patient data in real time, intelligent clinical alarm systems with advanced analytics, a clinical-decision support system (CDSS) and a virtual ICU solution can address the challenges in the intensive care environment. Bi-directional communication between connected medical devices and clinical information systems (CIS), particularly for smart infusion pumps programming and multi-parameter patient monitoring has proven to prevent adverse events in the high-acuity care environment. A well-integrated system with a centralised clinical dashboard with real-time insights on patients can help intensivists by prioritising patients that require higher levels of care.--BEGIN PROMO--

Research Highlights

Frost & Sullivan’s new research report on the Global Hospital-based Medical Device Connectivity Solutions Market, Forecast to 2022 provides a comprehensive analysis on the global medical device interoperability market with a competitive landscape covering clinical information technology (IT) systems vendors, medical device original equipment manufacturers (OEMs), vendor-agnostic third-party medical device data systems (MDDS) vendors, and healthcare system integrators. Please reach out to us to know more about medical device interoperability solutions and numerous methods to establish connectivity of your medical devices with the hospital network regardless of device types.

Presented Segmentation:

  • Clinical IT Systems Vendors
  • Medical Device OEMs
  • Vendor-Agnostic Connectivity Vendors
  • Healthcare System Integrators

Key Issues Addressed

  • What are the key market trends and industry dynamics in the medical device connectivity market? What is the future potential for medical device connectivity solutions?
  • What is the current market scenario? How much growth is expected? Which are the major market segments? What will be the impact of external trends on each business segment?
  • Who are the major participants in the global market for medical device connectivity? What are their solution offerings, product features and technical specifications?
  • What is driving the market? What are the restraints impacting growth opportunities for medical device connectivity in the global market?
  • What are the important business model considerations for healthcare stakeholders and providers? Are there any unmet customer needs? Is there an untapped opportunity in this market?
  • Are the connectivity solution offered by solution vendors today meeting end-user needs? Does it require additional enhancements to address critical business needs?
Fri, 27 Apr 2018 00:00:00 +0100
Healthcare Innovations in Emerging Economies http://www.frost.com/prod/servlet/sublib/display-report.do?id=D831-01-00-00-00 MedTech markets are among the most competitive markets worldwide, which are largely dominated by large multinational companies offering a wide range of products and solutions for top diseases. Emerging markets are vital to sustainable business growth and performance of top multinational companies, especially due to the huge patient turnover rates across most reputed healthcare facilities. The trend is evident in countries like India, Thailand, Singapore, Israel, Taiwan and Australia where high patient turnover rates are observed across medical imaging centers, operation theatres and outpatient services. This research service focuses on the need for sustainable sourcing of innovations across emerging economies to maintain market leadership and consistent business performance across competitive portfolios. The research service covers a snapshot of current industry scenario, including coverage of market growth, top companies, major drivers and challenges that are challenging the status-quo of companies operating in the emerging market especially, India, China, and Taiwan to name some. The chapters also cover gamechanging technologies and research initiatives that drive business performance in competitive portfolios. Key questions answered in this research service: 1. How the global medtech industry is segmented in terms of growth, technology change, customer segments and competitive scenario? 2. Who are the top competitors within the market, and how are they performing within emerging markets? What are the factors critical to survival of global companies , and their sustainable business growth within emerging economies? 3. Is there a strategic framework to address concerns of stakeholders along the value chain? What are the use cases of applying proprietary in-house data within this framework to aid in our internal decision making process? 4. How is the global technology innovation landscape for medical technologies? Who are the major players in the market? 5. What are the key patent filing trends impacting their competitive performance within the global medtech industry? Fri, 27 Apr 2018 00:00:00 +0100 Innovations in Immunoassays, Cancer Detection, Ophthalmic Disease Detection, Vital Signs Monitoring, CT Systems, and Ultrasound Imaging Systems http://www.frost.com/prod/servlet/sublib/display-report.do?id=D861-00-1F-00-00 The latest issue of Medical Imaging and Diagnostics TOE profiles innovations in the medical imaging and diagnostics industry. Some of the profiles covered include development of an automated immunoassay to detect Zika virus, artificial mole for cancer detection, artificial intelligence platform to detect diabetic retinopathy, brain mapping technology, urine test to detect cancer, continuous vital signs monitoring, ultra-fast ultrasound imaging, and mobile CT imaging. Medical Imaging and Diagnostics TechVision Opportunity Engine (TOE)'s mission is to analyze and report new and emerging technologies; advances in R&D, product development and regulatory matters specifically related to the areas of CT, MRI, NM, PET, Ultrasound and X-ray. In addition, relevant developments in fusion technologies, functional imaging technology, interventional cardiology and image guided surgery and healthcare IT related areas such as PACS, medical information storage, and disaster recovery/business continuance will also be covered. The Health and wellness cluster covers cutting-edge global developments in medical devices and imaging sectors such as biosensors, biomaterials, biomechanics, microtechnologies, nanotechnologies, assistive technologies and imaging technologies and platforms. Keywords: Automated immunoassay, cancer detection, artificial intelligence, brain mapping, urine test, remote patient management, ultra-high resolution CT system, ultra-fast ultrasound imaging, mobile CT imaging Fri, 27 Apr 2018 00:00:00 +0100 Innovations in Stem Cell-based Implants, ALS Treatment, CRISPR, and Personalized Cell Vaccines http://www.frost.com/prod/servlet/sublib/display-report.do?id=D758-00-77-00-00 This edition of the Genetic Technology TOE depicts trends across stem cell-based implants, ALS treatment, gene editing, and personalized cell vaccines. The clinical trials scenario for the treatment of cancer with vaccines is also depicted The Genetic Technology TechVision Opportunity Engine (TOE) presents the latest R&D developments and advances with an emphasis on opportunities to profit in the explosive field of genetic technology through technology transfer, joint ventures, and acquisitions. The complete gamut of genetic technology applications is covered including the latest developments in omics technologies; genetic, cellular, and alternative therapies; sequencing technologies; and genetically altered animals and plants. The Health & Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare. Keywords: Stem cell-based implants, amyotrophic lateral sclerosis, ALS, motor neurone disease, MND, Lou Gehrig's disease, gene editing, CRISPR, cancer vaccines, macular regeneration, personalized cell vaccine, ovarian cancer Fri, 27 Apr 2018 00:00:00 +0100 ECR 2018: Microwave Imaging, a New Modality Crossing into the Commercial Field http://www.frost.com/prod/servlet/sublib/display-market-insight.do?id=298492043 Wed, 25 Apr 2018 05:44:06 +0100 Growth Insights Real World Evidence Analytics Solutions Market http://www.frost.com/prod/servlet/sublib/display-report.do?id=K29B-01-00-00-00 Over the last 3-5 years, growing cost pressure on healthcare and pharmaceutical companies and a significant shift towards outcome based healthcare approach have resulted in companies increasingly adopting real world data and evidence solutions to optimize their operation and cost using analytics. Earlier, applications of RWE were largely limited to HEOR/pricing analytics; however digitalization of healthcare services and increased database access has resulted in applications expansion in other part of the value chain, including clinical trials, drug discovery, and life cycle management. During 2016 2021, global real world evidence analytics solutions market is expected to grow at ~16% CAGR to approximately 430 million by 2021. Favourable regulatory environment, preference of payers using RWD to understand the economic benefit outcomes, and achieved efficiency are some of the key market growth drivers. At present, the RWE analytics solutions market is moderately fragmented with presence of a number of life science companies, and database service providers. In addition, CROs are increasingly expanding their analytics and informatics capability to provide integrated solutions to their pharmaceutical clients. Traditionally, most database vendors have had relatively limited data analytics expertise and hence role of analytics vendors have become important in the industry. During 2017-2018, the RWE market has witnessed a number of partnership and acquisition activities as a number of industry stakeholders are looking to strengthen their technical expertise. Given existing capability gap, Frost & Sullivan expects this trend to continue in near future. So far, pharmaceutical companies have adopted a hybrid approach to manage real world evidence function. Most companies have invested in developing in-house teams and they partner with external vendors either on project basis or for specific therapeutic segments. Frost & Sullivan expects this trend to continue over the next 3-4 years as pharmaceutical companies will first look to establish processes and structures with in their organization, before relying on external vendors. Most vendors presently offer support based solutions, and cognitive and machine learning based DIY tools are still in work-in-progress, as different healthcare databases are still evolving and being explored. We expect a medium-moderate growth in adoption of DIY tools during the forecast period.--BEGIN PROMO--

Key Issues Addressed

  • What are they key market opportunities that make this an attractive market with significant future revenue potential for companies?
  • How are different regional market positioned to realize the available opportunities/growth potential?
  • What is the total market size and projected growth of real-world evidence analytics solutions?
  • What are the key challenges being faced by the clients? What are the key success factors for companies to remain relevant and competitive in this crowded market?
  • How product offerings in this market are likely to emerge? How transition across the value chain is happening to solve the unmet needs from customers?
  • How are current business models being replaced by innovative approaches to overcome existing challenges?
Tue, 24 Apr 2018 00:00:00 +0100
Innovations in Neuro Therapies, Wound Management, Injectable Bandages, Biosensors, Skin Electrocardiograms, and Medical Cables http://www.frost.com/prod/servlet/sublib/display-report.do?id=D852-00-1C-00-00 The latest edition of Medical Device TOE profiles a wide diversity of innovations impacting the healthcare industry. This issue identifies and describes early-stage innovations such as neuromodulation therapy to manage post-traumatic stress disorder (PTSD), implantable sensors for continuous medical monitoring, and bodyworn monitoring devices for mobile cardiac monitoring. Mature technologies that have been, or are nearing, commercialization, such as drug-coated balloons for peripheral artery disease, and a novel delivery vehicle for timed release of vaccines are also discussed. The Medical Device TechVision Opportunity Engine (TOE) analyzes and reports on new and emerging technologies and advances in R&D; product development; and regulatory matters related to neurology, ophthalmology, respiratory/anesthesia, wound care and management, surgical tools and instrumentation, drug delivery, orthopedics, endoscopy, cardiology, and monitoring. Medical devices and imaging technology and innovation research covers cutting-edge global developments in medical devices and imaging sectors such as biosensors, biomaterials, biomechanics, microtechnologies, nanotechnologies, assistive technologies, and imaging technologies and platforms. Keywords: Neuromodulation, combination products, targeted drug delivery, wearables, smart sensors Fri, 20 Apr 2018 00:00:00 +0100 Recent Advances in Anti-cancer and Antimicrobial Therapies http://www.frost.com/prod/servlet/sublib/display-report.do?id=D758-00-76-00-00 This edition of the Genetic Technology TOE depicts trends across anticancer and antimicrobial therapies. Selected antitumoral and antimicrobial platform technologies including radio-conjugate platforms and checkpoint inhibitor immunotherapies for enhancing targeted therapies, as well as, synthetic macromolecules for addressing multi-drug bacterial resistance have been profiled. The corresponding clinical trials scenario is depicted for Actinium-225-labeled humanized anti-CD33 monoclonal antibody HuM195 and UCART19. The Genetic Technology TechVision Opportunity Engine (TOE) presents the latest R&D developments and advances with an emphasis on opportunities to profit in the explosive field of genetic technology through technology transfer, joint ventures, and acquisitions. The complete gamut of genetic technology applications is covered including the latest developments in omics technologies; genetic, cellular, and alternative therapies; sequencing technologies; and genetically altered animals and plants. The Health & Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare. Keywords: Anti-cancer, antitumoral, antimicrobial, radio-conjugate platform, targeted therapy, cancer immunotherapy, checkpoint inhibitor therapy, synthetic macromolecules, multi-drug resistant bacteria, clinical trial analysis, HuM195, UCART19 Fri, 20 Apr 2018 00:00:00 +0100 Analysis of the APAC Cardiac Troponin Diagnostics Market, Forecast to 2021 http://www.frost.com/prod/servlet/sublib/display-report.do?id=P9F1-01-00-00-00 Cardiac troponins will continue to remain the gold standard for early diagnosis of acute myocardial infarction (AMI); however, the key challenge to address is the advent of a complementary biomarker to prevent repeat diagnosis. Multiplexing platforms should be harnessed for simultaneous testing of complementary biomarkers such as H-FABP, cardiac myosin binding C protein, co-peptin, and Pentraxin 3 (PTX3) that should be combined with utmost clinical utility. Chinese Food & Drug Administration (CFDA) and regional market access to APAC countries such as Indonesia and India will emerge as key markets with early commercial access with the new proposed CE regulatory guidelines that require lengthy approval times and clinical benefits. Furthermore, with the huge market opportunities in emerging APAC countries, unlike the conventional approach APAC market, access will take a center stage in parallel with Europe and the US. There is a general trend toward decentralization of laboratory testing in hospitals that have demonstrated an overall improvement in operational efficiency by 30% to 40%, further supported by the overall trends in pathology price cuts as an indirect measure to rising healthcare expenditure. Given the overall market trends in central lab testing, there will be a higher propensity toward adoption of POCT, with quantitative outcomes for mainstream clinical diagnosis. There will be an increase in adoption of POCT, which would eventually shrink the lab-based market for troponin biomarkers used for the diagnosis of MI. Physicians are demanding for a more accurate test which could reduce the burden in the healthcare settings. For patients under the acute critical conditions such as myocardial infarction, fast results and quick diagnosis are required. The rising prevalence of MI and increasing morbidity in the region will fuel the growth of diagnostic testings. Moreover, demands from physicians for more accurate and sensitive results will push researchers and investments for the diagnosis of MI.--BEGIN PROMO--

Key Issues Addressed

  • What are the key healthcare trends that could impact the APAC cardiac biomarker diagnostics market?
  • What are the market drivers and restraints that are impacting the market growth?
  • What are the unmet needs and the opportunities for the existing and emerging participants?
  • What are the segment shares of the key market participants?
  • How are companies dealing with the challenges in the market space?
  • What are the future trends and the forecast scenario of the AMI biomarkers diagnostics in a different region?
Mon, 16 Apr 2018 00:00:00 +0100
Innovations in RNA Interference and MicroRNA Therapies http://www.frost.com/prod/servlet/sublib/display-report.do?id=D951-00-1C-00-00 This Drug Discovery TechVision Opportunity Engine (TOE) depicts new life sciences trends across RNA targeting technologies, such as RNA interference and microRNA therapies, aiming for accelerating drug discovery and development. The power of druggable RNA propelling therapeutics discovery pathway is analyzed in-depth through notable innovations in microRNA-based platforms, self-delivered RNA interference-based liposomes, anti-code therapeutics, therapeutic ribonucleases, antisense drugs, RNA splicing modulation, exon skipping treatments, and microRNA programming. The corresponding clinical trial scenario involving RNA-based treatments is also depicted. The Drug Discovery TechVision Opportunity Engine (TOE) reports and analyzes about the latest developments in drug discovery and therapeutics, thereby providing an opportunity to acquire strategic insights into crucial developments in this industry domain. Technologies profiled include those used for biomarker and target discovery such as high throughput screening, signal transduction, micro array, RNAi, metabolomics, toxicogenomics, biosensors and nanotechnology. In addition to these, a fair focus shall be dedicated to the latest trends in therapeutic approaches across a diversity of diseases including infectious, genetic, metabolic, neurological, cardiac, and autoimmune disorders. The Health and Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare. Keywords: microRNA-based platform, self-delivering RNA interference-based liposomes, next-generation therapeutics, short interfering RNA molecules, therapeutic anti-code candidates, therapeutic ribonucleases, transfer-RNA, precursor micro-RNA, RNAi therapeutics, hereditary amyloidoisis, second generation antisense drugs, RNA splicing modulation, cancer, exon skipping treatment, mRNA drug programming Fri, 13 Apr 2018 00:00:00 +0100 Innovations in Gene Delivery Platform Technology http://www.frost.com/prod/servlet/sublib/display-report.do?id=D758-00-75-00-00 This edition of the Genetic Technology TOE depicts the current landscape and the new life sciences trends across gene delivery platform technologies. Since immuno-oncology and rare diseases are the most focused therapeutic areas in recent times, the TOE highlights recent innovations in these fields. The corresponding clinical trials scenario is also depicted. The Genetic Technology TechVision Opportunity Engine (TOE) presents the latest R&D developments and advances with an emphasis on opportunities to profit in the explosive field of genetic technology through technology transfer, joint ventures, and acquisitions. The complete gamut of genetic technology applications is covered including the latest developments in omics technologies; genetic, cellular, and alternative therapies; sequencing technologies; and genetically altered animals and plants. The Health & Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare. Keywords: Gene delivery platform technology, genetically modified probiotic bacteria, immuno-oncology, adeno-associated virus gene therapy, non-viral gene delivery, hematopoietic stem cells, anti-tumor proteins Fri, 13 Apr 2018 00:00:00 +0100 Global Biologics Contract Development & Manufacturing Organization (CDMO) Market Companies-to-Action http://www.frost.com/prod/servlet/sublib/display-report.do?id=MD88-01-00-00-00 The study on the "Global Biologics Contract Development & Manufacturing Organizations (CDMO) Market: Companies-to-Action" presents an overview of the global biologics development and manufacturing landscape with an emphasis on the seven leading CDMOs in the market. The study highlights the shifting focus and investments of bio-pharma companies toward biologics development and manufacturing, which is attributed to the growing demand for innovative therapies as well as the loss of patent exclusivity of the leading pharma products. The biologics manufacturing industry is presently in a growth stage owing to factors such as complexity of molecules and complex manufacturing processes. This presents an immense potential for the market with pharmaceutical MNCs looking for outsourcing partners providing them with biologics development and manufacturing services at comparatively lower costs. The advent of personalized medicine calls for a shift toward flexible, small-volume manufacturing using single-use/ disposable bioreactors and using bio-analytical capabilities, thus exploring continuous processing technologies in modular facilities. Presently, the outsourcing of bio-analytical activities is comparatively lower across the industry, which provides ample opportunities to outsourcing partners in terms of services such as bio-analytical testing by means of building entrenched relationships with pharma MNCs. Further, bio-CDMOs are making use of advanced continuous manufacturing processes as opposed to the traditional batch processes, which increases the time-to-market of the biologics and help the firms meet the growing demand. CDMOs are adopting several newer business models such as risk sharing models and value-based models to achieve a competitive edge in the ever-changing biologics manufacturing landscape. Using these approaches, there are also able to meet specific needs of their pharma partners in terms of drug development through out-licensing of the development and manufacturing expenses and acquiring flexible and modular manufacturing capabilities, thereby meeting the demand. In addition to the above-mentioned strategic analysis, this report also provides information on some of the recent collaborations of the bio-CDMOs.--BEGIN PROMO--

Key Issues Addressed

  • What are the current growth opportunities in the bio-CDMO market? What are some of the external factors that affect this market?
  • Which are the key bio-CDMOs that are introducing unique and innovative solutions in the market? How do these solutions transform the market?
  • How will the bio-CDMO market transform the industry paradigms in the next five years?
  • What are the strategic imperatives to be adopted by the bio-CDMOs to bring about this market transformation?
  • What is the growth potential of this rapidly expanding Bio-CDMO market?
  • Which CDMO business model is best suited to meet the growing outsourcing needs of the biopharmaceutical industry?
Thu, 12 Apr 2018 00:00:00 +0100
Global Life Sciences Industry Outlook, 2018 http://www.frost.com/prod/servlet/sublib/display-report.do?id=MDB0-01-00-00-00 The global life sciences industry is onto a rocking start with the surge in CEO confidence from US tax reforms, rollicking equity markets and strengthening the global economy. Healthcare digitization, democratization creating explosion in patient data, emergence of value-based reimbursement models, and healthcare consumerism shifting the risk from payers to providers have provided a strong impetus to the growth of the life sciences industry. The convergence of biopharmaceuticals, drug delivery devices, and companion diagnostics enabled by the digital connectivity is driving regulatory and commercial changes in many exciting ways for the industry. With the synergistic effect of advanced technologies, such as Artificial Intelligence, Big Data analytics, and cloud computing on the traditional life sciences industry, growth could be even faster in 2018. The paradox of the new growth rate is that its taking place even as the industry is grappling with the larger question when will precision healthcare become a reality? In this research deliverable, Frost & Sullivan s senior analyst team provides bold perspectives and predictions for the global life sciences industry in 2018. The markets covered include pharmaceuticals and biotechnology, in vitro diagnostics, and research tools. The analysis captures the sectoral and regional trends and predictions that are expected to transpire over the upcoming year as organizations shift to prepare for the future. The key objective of this research service is to enable clients to identify growth opportunities and devise potential growth strategies in the transformational life sciences ecosystem. The report also provides a futuristic perspective on the competitive landscape, market, and technology trends. Frost & Sullivan s life sciences experts envisage: Payers rapidly moving toward outcome-based assessment models and trials. Drug companies will witness a shift from quantity-based, fee-for- service model to value and outcome-based contracts. Preventive healthcare driven by predictive analytics to determine the likelihood of disease progression. Several oncology focused-startup companies will take the lead in Big Data. Lab test payments significantly cut by PAMA regulations. Revision of the EU-IVDR triggers delays in the new product launch. Reimbursement for digital therapeutics will become critical. X-as-a-Service Model (XaaS) will open new revenue streams and impact top line revenues of genomic services providers. Small and mid-sized companies attracting Big Pharma. Favorable tax reforms and competition for new assets could, in turn, lead to higher valuations and product deal amounts.--BEGIN PROMO--

Key Issues Addressed

  • What are the main factors that will influence the size and direction of the global life sciences industry in 2018?
  • How does the industry outlook vary from region to region?
  • What is the outlook for pharmaceutical & biotechnology and IVD & research tools in each region during 2018?
  • What technology developments in the global life sciences industry in 2017 will have an impact during 2018?
  • What will be the key growth opportunities and strategic imperatives for companies in 2018?
Mon, 9 Apr 2018 00:00:00 +0100
Innovations in Synthetic Biology and Sequencing Technology http://www.frost.com/prod/servlet/sublib/display-report.do?id=D758-00-74-00-00 This edition of the Genetic Technology TOE depicts life sciences trends across synthetic biology and sequencing technology. Engineered chimeric molecules and promoters, nanobody platforms, next-generation RNA sequencing technologies coupled with machine learning systems, are some of the most relevant innovations profiled. Vector delivery platform technologies expected to undergo clinical studies in the coming quarter are also depicted. The Genetic Technology TechVision Opportunity Engine (TOE) presents the latest R&D developments and advances with an emphasis on opportunities to profit in the explosive field of genetic technology through technology transfer, joint ventures, and acquisitions. The complete gamut of genetic technology applications is covered including the latest developments in omics technologies; genetic, cellular, and alternative therapies; sequencing technologies; and genetically altered animals and plants. The Health & Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare. Keywords: Engineered chimeric molecule, next-gen RNA sequencing, machine learning, engineered promoters, gene expression, nanobody, immunotherapy, vector delivery platform Fri, 6 Apr 2018 00:00:00 +0100 Asia-Pacific Healthcare Outlook, 2018 http://www.frost.com/prod/servlet/sublib/display-report.do?id=P9E1-01-00-00-00 The healthcare industry in Asia-Pacific (APAC) is expected to grow at 11.1% in 2018, making it one of the fastest growing regions in the world, as the global healthcare economy averages an annual growth rate of 4.8%. This positive growth is fuelled by increasing adoption of technology, innovative healthcare access programs, and delivery of care outside traditional hospital settings. Frost & Sullivan projects the APAC healthcare market to grow to $517 billion in 2018. For the region, healthcare challenges of access and affordability of new technology demand complex and innovative solutions from all industry stakeholders. Key industry issues that deserve attention include policy innovation, support for new business models, development of patient-focused technology platforms, and the evolving role of consumers in healthcare. These emerging trends create growth opportunities for industry participants including pharmaceuticals, diagnostics, and medical technology manufacturers, digital health vendors, and healthcare service providers. The role of healthcare consumers is changing dramatically in APAC. Digital technology is enabling access to information and care; hence consumers are able to choose where, how, and by whom they would like to be treated. This is changing every business model in the region. With this major industry transition as the background, some of the Growth Opportunities discussed in this year s Outlook cover the following areas: Private Health Insurance Medical Tourism Healthcare Provider Infrastructure Imaging Analytics Patient Monitoring Platforms Mental Health Regenerative Medicine Biosimilars Cloud and AI. An important global trend that is currently missing in APAC is the introduction of value- and outcomes-based payment and reimbursement models. Industry suppliers, including IT vendors, medical technology companies and pharmaceuticals, are partnering with public and private payers to introduce outcomes-based reimbursement models for expensive therapeutic products and services in other parts of the world. In 2018, Japan could be the first in APAC to introduce an outcomes-based reimbursement model for Novartis CAR-T therapy, with China potentially following suit. On the other hand, personalization combined with consumer empowerment will be the key ingredient for disease prevention and patient wellness. Direct-to-consumer gene sequencing is moving toward services and solutions as companies like Prudential, iCarbonX, and Healthi have introduced personalized wellness interventions. On the other hand, companies like Thorne Research and Imagene Labs will make available personalized over-the-counter nutritional supplements and skin care products, respectively, and that too on a subscription model. In a nutshell, 2018 is expected to be the year when APAC truly transforms industry business models, with technology and data transparency being the key enablers. Our outlook discusses the qualitative and quantitative factors driving this transformation. Tue, 3 Apr 2018 00:00:00 +0100 Innovations in Artificial Intelligence and Genomics Research http://www.frost.com/prod/servlet/sublib/display-report.do?id=D758-00-73-00-00 This edition of the Genetic Technology TOE depicts life sciences trends across genomics. Discovery of genetic risk factors for common complex diseases, an artificial intelligence platform for assembling biological data, advancing precision oncology via whole genome sequencing, and cutting edge adjacent technologies have been profiled. Ongoing clinical trials for whole genome sequencing have also been presented. The Genetic Technology TechVision Opportunity Engine (TOE) presents the latest R&D developments and advances with an emphasis on opportunities to profit in the explosive field of genetic technology through technology transfer, joint ventures, and acquisitions. The complete gamut of genetic technology applications is covered including the latest developments in omics technologies; genetic, cellular, and alternative therapies; sequencing technologies; and genetically altered animals and plants. The Health & Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare. Keywords: Genomics, genetic risk factors, artificial intelligence, precision oncology, whole genome sequencing, adjacent technologies Fri, 30 Mar 2018 00:00:00 +0100 Advancements in Biomarkers, Atmospheric Water Generation, Artificial Intelligence, Liquid-repellent Surfaces, and 3D Printed Stethoscopes http://www.frost.com/prod/servlet/sublib/display-report.do?id=D707-00-73-00-00 This edition of the Inside R&D TOE depicts developments associated with biomarkers, artificial intelligence, liquid-repellent surfaces, and 3D printed stethoscopes. The TOE also focuses on solar powered atmospheric water generation technology. Inside R&D TechVision Opportunity Engine (TOE) covers global innovations that are in research and development in virtually all technology areas. We provide intelligence and insights on innovations spanning a wide variety of industry areas, including automation, electronics, sensors, information and communication technologies, manufacturing, health, wellness, medical devices, pharma, biotechnology, materials, coatings, renewable fuels, automotive, power systems, sustainable energy solutions and innovations that contribute to a cleaner and greener environment. Keywords: Preeclampsia biomarker, liquid-repellent coating, 3D printed stethoscope Fri, 30 Mar 2018 00:00:00 +0100 Innovations in Artificial Intelligence, Wearable Monitoring of Vital Signs, Ultrasound Imaging, and SPECT http://www.frost.com/prod/servlet/sublib/display-report.do?id=D861-00-1E-00-00 The latest issue of Medical Imaging and Diagnostics TOE profiles innovations in the medical imaging and diagnostics industry. Some of the profiles covered include development of an artificial intelligence platform for diagnosing autism, wearable sensing devices for continuous monitoring of vital signs, augmented reality-based ultrasound imaging, SPECT imaging for diagnosing clinical depression, and solutions that can predict cardiovascular risk by observing eye images. Medical Imaging and Diagnostics TechVision Opportunity Engine (TOE)'s mission is to analyze and report new and emerging technologies; advances in R&D, product development and regulatory matters specifically related to the areas of CT, MRI, NM, PET, Ultrasound and X-ray. In addition, relevant developments in fusion technologies, functional imaging technology, interventional cardiology and image guided surgery and healthcare IT related areas such as PACS, medical information storage, and disaster recovery/business continuance will also be covered. The Health and wellness cluster covers cutting-edge global developments in medical devices and imaging sectors such as biosensors, biomaterials, biomechanics, microtechnologies, nanotechnologies, assistive technologies and imaging technologies and platforms. Keywords: Artificial intelligence, SPECT, augmented reality, ultrasound imaging, radiology ultrasound system, smartphone diagnostics test reader system, cardiovascular risk prediction solutions Fri, 30 Mar 2018 00:00:00 +0100 Medical Device Interoperability Solutions to Address Intensivist Crisis in Critical Care http://www.frost.com/prod/servlet/sublib/display-market-insight.do?id=298423467 Tue, 27 Mar 2018 03:44:31 +0100 What Next after EHR Implementation? http://www.frost.com/prod/servlet/sublib/display-market-insight.do?id=298423435 Tue, 27 Mar 2018 03:37:43 +0100 Transforming Healthcare Through Excellence in Patient Experience http://www.frost.com/prod/servlet/sublib/display-market-insight.do?id=298423403 Tue, 27 Mar 2018 03:22:55 +0100